These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11078415)

  • 1. Attenuation of puromycin aminonucleoside-induced glomerular lesions in rats by CGS 26303, a dual neutral endopeptidase/endothelin-converting enzyme inhibitor.
    Feldman DL; Mogelesky TC; Chou M; Jeng AY
    J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S342-5. PubMed ID: 11078415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of big ET-1-induced pressor response by an orally active dual inhibitor of endothelin-converting enzyme and neutral endopeptidase 24.11.
    Trapani AJ; De Lombaert S; Kuzmich S; Jeng AY
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S69-71. PubMed ID: 8587471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes.
    Tikkanen I; Tikkanen T; Cao Z; Allen TJ; Davis BJ; Lassila M; Casley D; Johnston CI; Burrell LM; Cooper ME
    J Hypertens; 2002 Apr; 20(4):707-14. PubMed ID: 11910307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The peptidase inhibitor CGS-26303 increases endothelin converting enzyme-1 expression in endothelial cells through accumulation of big endothelin-1.
    Raoch V; Martinez-Miguel P; Arribas-Gomez I; Rodriguez-Puyol M; Rodriguez-Puyol D; Lopez-Ongil S
    Br J Pharmacol; 2007 Oct; 152(3):313-22. PubMed ID: 17643133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective effects of a dual endothelin converting enzyme/neutral endopeptidase inhibitor on the development of pulmonary hypertension secondary to cardiac dysfunction in the rat.
    Dai ZK; Hsieh CC; Chai CY; Wu JR; Jeng AY; Chou SH; Wu BN; Yeh JL; Chen IJ; Tan MS
    Pediatr Pulmonol; 2010 Nov; 45(11):1076-85. PubMed ID: 20658482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CGS 34043: a non-peptidic, potent and long-acting dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11.
    Trapani AJ; De Lombaert S; Beil ME; Bruseo CW; Savage P; Chou M; Jeng AY
    Life Sci; 2000; 67(9):1025-33. PubMed ID: 10954036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of a specific endothelin receptor A antagonist and an angiotensin-converting enzyme inhibitor on glomerular mRNA levels for extracellular matrix components, metalloproteinases (MMP) and a tissue inhibitor of MMP in aminonucleoside nephrosis.
    Ebihara I; Nakamura T; Tomino Y; Koide H
    Nephrol Dial Transplant; 1997 May; 12(5):1001-6. PubMed ID: 9175058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a selective neutral endopeptidase and a nonselective neutral endopeptidase/endothelin-converting enzyme inhibitor on lipopolysaccharide-induced endotoxaemia in anaesthetized Sprague-Dawley rats.
    Pham D; Jeng AY; Escher E; Sirois P; Battistini B
    J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S362-6. PubMed ID: 11078421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats.
    Emoto N; Raharjo SB; Isaka D; Masuda S; Adiarto S; Jeng AY; Yokoyama M
    Hypertension; 2005 Jun; 45(6):1145-52. PubMed ID: 15897363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological properties of CGS 35066, a potent and selective endothelin-converting enzyme inhibitor, in conscious rats.
    Trapani AJ; Beil ME; Bruseo CW; De Lombaert S; Jeng AY
    J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S40-3. PubMed ID: 11078331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of CGS 31447, a potent and nonpeptidic endothelin-converting enzyme inhibitor.
    Shetty SS; Savage P; DelGrande D; De Lombaert S; Jeng AY
    J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S68-70. PubMed ID: 9595403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological profile of a non-peptidic dual inhibitor of neutral endopeptidase 24.11 and endothelin-converting enzyme.
    De Lombaert S; Ghai RD; Jeng AY; Trapani AJ; Webb RL
    Biochem Biophys Res Commun; 1994 Oct; 204(1):407-12. PubMed ID: 7945387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of dual endothelin-converting enzyme/neutral endopeptidase inhibitors, CGS 26303 and CGS 26393, on lipopolysaccharide or interleukin-1 beta-stimulated release of endothelin from guinea pig tracheal epithelial cells.
    Pelletier S; Battistini B; Jeng AY; Sirois P
    J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S10-2. PubMed ID: 9595386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the ECE/NEP inhibitor CGS 34225 on the big ET-1-induced pressor response and plasma atrial natriuretic peptide concentration in conscious rats.
    Trapani AJ; Beil ME; Bruseo CW; Fink CA; Hoyer D; Savage P; Jeng AY
    Clin Sci (Lond); 2002 Aug; 103 Suppl 48():102S-106S. PubMed ID: 12193065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CGS 35601 and its orally active prodrug CGS 37808 as triple inhibitors of endothelin-converting enzyme-1, neutral endopeptidase 24.11, and angiotensin-converting enzyme.
    Trapani AJ; Beil ME; Bruseo CW; Savage P; Firooznia F; Jeng AY
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S211-5. PubMed ID: 15838282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained improvement of cardiac function and prevention of cardiac remodeling after long-term dual ECE-NEP inhibition in rats with congestive heart failure.
    Mulder P; Barbier S; Monteil C; Jeng AY; Henry JP; Renet S; Thuillez C
    J Cardiovasc Pharmacol; 2004 Apr; 43(4):489-94. PubMed ID: 15085059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rat big endothelin-1-induced bronchoconstriction and vasoconstriction in the isolated perfused rat lung: role of endothelin converting enzyme and neutral endopeptidase 24.11.
    Held HD; Raschak M; Uhlig S
    Naunyn Schmiedebergs Arch Pharmacol; 1997 May; 355(5):619-24. PubMed ID: 9151301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats.
    Daull P; Benrezzak O; Arsenault D; Pheng LH; Blouin A; Cayer J; Beaudoin M; Belleville K; Sirois P; Nantel F; Jeng AY; Battistini B
    Am J Hypertens; 2005 Dec; 18(12 Pt 1):1606-13. PubMed ID: 16364833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent and selective non-peptidic inhibitors of endothelin-converting enzyme-1 with sustained duration of action.
    De Lombaert S; Blanchard L; Stamford LB; Tan J; Wallace EM; Satoh Y; Fitt J; Hoyer D; Simonsbergen D; Moliterni J; Marcopoulos N; Savage P; Chou M; Trapani AJ; Jeng AY
    J Med Chem; 2000 Feb; 43(3):488-504. PubMed ID: 10669576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of endothelin-converting enzyme inhibitors on hemolysate-induced morphological changes and production of endothelin-1 in bovine cerebrovascular endothelial cells.
    Kwan AL; Lin CL; Chang CZ; Winardi D; Yen CP; Howng SL; Jeng AY
    J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S160-2. PubMed ID: 11078366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.